All Stories

  1. NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/ mTOR phosphorylation

    Article • OncoTargets and Therapy, January 2015, Taylor & Francis

    Dr zhihua sun